JP2003530349A - 皮膚病用の使用方法及び皮膚病用薬剤 - Google Patents

皮膚病用の使用方法及び皮膚病用薬剤

Info

Publication number
JP2003530349A
JP2003530349A JP2001574107A JP2001574107A JP2003530349A JP 2003530349 A JP2003530349 A JP 2003530349A JP 2001574107 A JP2001574107 A JP 2001574107A JP 2001574107 A JP2001574107 A JP 2001574107A JP 2003530349 A JP2003530349 A JP 2003530349A
Authority
JP
Japan
Prior art keywords
thyroxine
treatment
thyroid hormone
skin
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001574107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530349A5 (OSRAM
Inventor
ヘイノ，ペッカ
Original Assignee
イプサット テラピース オイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イプサット テラピース オイ filed Critical イプサット テラピース オイ
Publication of JP2003530349A publication Critical patent/JP2003530349A/ja
Publication of JP2003530349A5 publication Critical patent/JP2003530349A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2001574107A 2000-04-06 2001-02-05 皮膚病用の使用方法及び皮膚病用薬剤 Pending JP2003530349A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20000818A FI107018B (fi) 2000-04-06 2000-04-06 Dermatologinen käyttö ja valmiste
FI20000818 2000-04-06
PCT/FI2001/000100 WO2001076589A1 (en) 2000-04-06 2001-02-05 Dermatological use and a dermatological preparation

Publications (2)

Publication Number Publication Date
JP2003530349A true JP2003530349A (ja) 2003-10-14
JP2003530349A5 JP2003530349A5 (OSRAM) 2007-06-07

Family

ID=8558139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001574107A Pending JP2003530349A (ja) 2000-04-06 2001-02-05 皮膚病用の使用方法及び皮膚病用薬剤

Country Status (14)

Country Link
US (2) US20030144359A1 (OSRAM)
EP (1) EP1274416A1 (OSRAM)
JP (1) JP2003530349A (OSRAM)
AU (1) AU2001235506A1 (OSRAM)
CA (1) CA2405425A1 (OSRAM)
CH (1) CH695983A5 (OSRAM)
DE (1) DE10196025T1 (OSRAM)
DK (1) DK200201483A (OSRAM)
ES (1) ES2193003B1 (OSRAM)
FI (1) FI107018B (OSRAM)
GB (1) GB2377380B (OSRAM)
NO (1) NO20024810L (OSRAM)
SE (1) SE0202886L (OSRAM)
WO (1) WO2001076589A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
JP2007505837A (ja) * 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート 甲状腺ホルモンアナログおよび新脈管形成における使用の方法
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB859546A (en) * 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3198702A (en) * 1960-03-17 1965-08-03 Arthur A Hellbaum Method for treating skin burns
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine
US5951989A (en) * 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
EP1173163B1 (en) * 1999-04-26 2006-06-21 Elliot Danforth, Jr. Pharmaceutical compositions of tetrac and methods of use thereof
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels

Also Published As

Publication number Publication date
SE0202886D0 (sv) 2002-10-01
US20050272817A1 (en) 2005-12-08
US20030144359A1 (en) 2003-07-31
DE10196025T1 (de) 2003-03-13
DK200201483A (da) 2002-10-03
AU2001235506A1 (en) 2001-10-23
GB0222880D0 (en) 2002-11-13
ES2193003A1 (es) 2003-10-16
NO20024810L (no) 2002-12-06
EP1274416A1 (en) 2003-01-15
GB2377380A (en) 2003-01-15
FI20000818A0 (fi) 2000-04-06
FI107018B (fi) 2001-05-31
ES2193003B1 (es) 2005-02-01
GB2377380B (en) 2004-07-14
CA2405425A1 (en) 2001-10-18
WO2001076589A1 (en) 2001-10-18
CH695983A5 (de) 2006-11-15
NO20024810D0 (no) 2002-10-04
SE0202886L (sv) 2002-12-02

Similar Documents

Publication Publication Date Title
AU776318B2 (en) Topical zinc compositions and methods of use
Katayama et al. Exacerbation of psoriasis induced by indomethacin
EP0719145B1 (en) Nitric oxide donor composition for treatment of anal disorders
KR100479669B1 (ko) Igf-1의레벨증가에유용한l-아세틸카르니틴,l-이소발레릴카르니틴,l-프로피오닐카르니틴의용도
JP2003530349A5 (OSRAM)
US20030144359A1 (en) Dermatological use and a dermatological preparation
US4590213A (en) Anti-anxiety method
JPS62246515A (ja) タモキシフエン又はその製薬上認容性塩を含有する乾癬の治療剤
JPH0892180A (ja) Ｌ−カルニチン塩および化粧用および皮膚病処置用医薬組成物
AU754420B2 (en) Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
JPH05505819A (ja) 尋常性ざ瘡の治療および老化遅延のための組成および方法
JPH0778011B2 (ja) 皮脂漏症を減少させる治療剤
JP2002542284A (ja) テトラックの薬学組成物およびその使用方法
US5744157A (en) Preparation for maintaining and/or increasing muscular power and body cell mass
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
WO1986005395A1 (fr) Composition de traitement de dermatoses
JP3830963B2 (ja) 乾癬治療
EP0228239B1 (en) Preparation of a medicament for arthritis and rheumatism
DE69426986T2 (de) Behandlung von laminitis
JPH0563452B2 (OSRAM)
JP2522962B2 (ja) 乾癬治療剤
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
JP2002500181A (ja) ジスキネジーの処置
JP2002529506A (ja) リルゾールおよびα−トコフェロールの組み合わせ剤
IT8247658A1 (it) Medicamenti a base di derivati condensati dell'imidazolo per il trattamento di disturbi urinari

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061219

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070626